On Monday, GSK plc GSK stock is trading higher on highly positive clinical data from two separate lung cancer trials, ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

GSK plc GSK reported fourth-quarter 2025 core earnings of 68 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 64 cents. Core earnings increased 10% year over year ...

GSK PLC GSK +1.87% shares rose 4.74% to £18.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX -0.28% rising 0.44% to 10,697.57.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

GSK stock in London traded around 1,858.5 pence on September 15, 2026 after the company agreed a deal worth up to USD 750 million for a blood cancer drug. Berenberg raised its rating to Buy and lifted ...

GSK stock increased 0.4% following Berenberg's upgrade to buy with £22 target and announcement of $750M Chimagen deal for multiple myeloma therapy.

GSK shares climbed after the company reported encouraging clinical trial results for two lung cancer treatments, strengthening its oncology strategy despite mixed analyst views on the stock.

GSK PLC GSK +1.87% shares shed 1.55% to £17.76 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX -0.28% falling 0.57% to 10,608.92.

GSK stock rose 0.4% after Berenberg upgraded to buy with a £22 target and GSK announced a $750M deal with Chimagen Biosciences for a multiple myeloma asset.

Fintel reports that on November 7, 2025, JP Morgan Cazenove reiterated coverage of GSK plc - Depositary Receipt (NYSE:GSK) with a Underweight recommendation. As of October 30, 2025, the average ...

GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid ...